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Abstract 
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation intervention that 
modifies cortical excitability according to the stimulation parameters. Preclinical and clinical 
studies in healthy volunteers suggest that tDCS induces neuroplastic alterations of cortical 
excitability, which might explain its clinical effects in major depressive disorder (MDD). We 
therefore examined whether tDCS, as compared to the antidepressant sertraline, increases plasma 
brain-derived neurotrophic factor (BDNF) levels, a neurotrophin associated with neuroplasticity. 
Patients (n=73) with major depressive disorder were randomized to active/sham tDCS and 
sertraline/placebo (four groups) in this 6-week, double-blind, placebo-controlled trial. We measured 
BDNF plasma levels at baseline and endpoint, observing no significant changes of BDNF levels 
after treatment. In addition, no significant changes were observed in responders and non-responders 
as well as no relationships between BDNF levels and clinical and psychopathological variables 
related to depression. Thus, in one of the few placebo-controlled trials evaluating BDNF changes 
over an antidepressant treatment course, we did not observe BDNF increase regardless of clinical 
improvement in depressed patients. Regarding tDCS, BDNF plasma levels might not be a good 
candidate biomarker to evaluate depression improvement or be a predictor of response in patients 
treated with tDCS, as our results showed that BDNF increase was not necessary to induce clinical 
response. Finally, our findings do not support a relationship between BDNF and improvement of 
depression. 
Keywords 
Brain-derived neurotrophic factor; transcranial direct current stimulation; major depressive 
disorder; sertraline; non-invasive brain stimulation; neuroplasticity.  
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1. Introduction 
  Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique 
that induces polarity-dependent changes of cortical excitability (Nitsche and Paulus, 2000). When 
performed for several minutes, a single tDCS session can induce cortical excitability changes 
outlasting the period of stimulation for more than 1 hour (Batsikadze et al., 2013; Brunoni et al., 
2012b; Monte-Silva et al., 2013; Monte-Silva et al., 2010; Nitsche et al., 2008; Nitsche et al., 2003); 
pointing out that changes in synaptic plasticity are involved in tDCS mechanisms. In fact, 
neurophysiological studies showed that tDCS-induced plasticity is calcium-dependent and involves 
glutamatergic synapses (for a review see (Stagg and Nitsche, 2011)). When applied daily for several 
days, tDCS seems to have therapeutic properties in the treatment of psychiatric disorders (Kuo et 
al., 2013), and, among those, tDCS has been particularly investigated for major depressive disorder 
(MDD) (Brunoni et al., 2012a), with recent and large trials showing positive outcomes (Brunoni et 
al., 2013b; Loo et al., 2012). Nonetheless, the mechanisms of action underlying tDCS 
antidepressant response are still unknown; it has been proposed that daily, anodal tDCS over the left 
dorsolateral prefrontal cortex (DLPFC) reverses the hypoactivity in this area, which is observed in 
MDD (Mayberg et al., 2000); subsequently leading to depression improvement. 
In recent years, the neurotrophin hypothesis of depression has been implicated in MDD 
pathophysiology. In short, this hypothesis advocates that the depressive state is associated with 
lower expression of the brain-derived neurotrophic factor (BDNF), a neurotrophin essential to 
synaptic strengthening and neuronal survival (Duman and Monteggia, 2006), and that 
antidepressant effects would involve up-regulation of BDNF levels as a key neurobiological 
pathway for depression improvement. In accordance, Karege et al. (2002) and Shimizu et al. (2003) 
showed that BDNF blood levels are lower in depressed vs. healthy subjects and that BDNF levels 
increase during pharmacological treatment. Moreover, some depression symptoms, such as verbal 
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memory impairment, are associated with low BDNF levels (Grassi-Oliveira et al., 2008). Indeed, 
recent meta-analyses (Brunoni et al., 2008; Molendijk et al., 2013; Sen et al., 2008) found that 
BDNF is lower in depressed vs. healthy participants and that it increases during treatment; although 
Molendijk et al. (2013) stated that such claims might be “slimmer as was initially thought and 
amidst a lot of noise” such as evidence of publication bias and presence of confounding factors, 
highlighting the need of further BDNF studies evaluating its role as a treatment biomarker. Another 
issue is that virtually all studies evaluating BDNF changes after antidepressant treatment were not 
placebo-controlled trials; therefore not disentangling treatment effects from the natural changes 
over the course of illness. Besides, one cannot rule out whether the BDNF changes observed in 
pharmacological interventions occur due to a neuroplastic effect or simply due to direct effects in 
BDNF peripheral levels- for instance, antidepressants release BDNF stored in platelets (Watanabe 
et al., 2010). In this context, evaluating BDNF changes after therapies having no pharmacokinetic 
properties, such as somatic treatments, might be useful.  
Nevertheless, as compared to pharmacological interventions, for somatic stimulation 
therapies (such as electroconvulsive therapy [ECT], repetitive transcranial magnetic stimulation 
[rTMS] and tDCS), the role of BDNF in inducing antidepressant response has been scarcely 
investigated, with mixed or negative findings of BDNF increase, although most studies were not 
sham-controlled and therefore methodologically limited (e.g., Gedge et al., 2012 and Lang et al., 
2006). For tDCS, only the sham-controlled study of Palm et al. (2013) investigated whether BDNF 
serum levels increased after tDCS treatment of patients suffering from MDD, and report unchanged 
levels after treatment. However, the authors acknowledged some study limitations such as small 
sample size, short time period between the first and the second BDNF collections and overall 
absence of active vs. sham tDCS effects on clinical improvement. Further, they did not compare the 
antidepressant effects of tDCS to a pharmacological therapy, in which the evidence of BDNF 
increase might be more robust. Considering the putative advantages of tDCS in daily practice (low 
cost, portability, ease of use) and its clinical efficacy demonstrated in our recent study (Brunoni et 
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al., 2013b), tDCS alone and combined with pharmacological therapy could be interesting 
antidepressant strategies. In this regard, investigating whether BDNF levels increase after these 
interventions is important to better understand the pathophysiological mechanisms involved in 
antidepressant response.  
Therefore, considering that (1) animal studies (e.g., (Fritsch et al., 2010)) showed that direct 
current stimulation promotes BDNF-dependent synaptic plasticity; (2) tDCS effects are associated 
with neuroplasticity and; (3) tDCS has antidepressant effects; we hypothesized in our placebo-
controlled study that BDNF levels would increase after tDCS and pharmacological antidepressant 
treatment and such improvement would be associated with clinical response. These hypotheses 
were assessed using data from our previous trial, in which we compared the effects of sertraline vs. 
tDCS in patients with unipolar depression, as described below.  
 
2. Experimental Procedures 
2.1 Study design 
The Sertraline vs. Electric Current Therapy for Treating Depression Clinical Study 
(SELECT-TDCS) took place from March 2010 to September 2011 at University Hospital, 
University of São Paulo, Brazil. This study was registered in clinicaltrials.gov (NCT01033084), and 
approved by the Local and National Ethics Committee with all participants providing written, 
informed consent. The main methodological aspects and results are described elsewhere (Brunoni et 
al., 2011b; Brunoni et al., 2013b).  
In short, SELECT-TDCS was a factorial, sham-controlled trial in which 120 participants 
with depression were randomized using a 1:1:1:1 permuted block randomization method into four 
treatment groups: (1) sham-tDCS / placebo-pill (further referred as placebo); (2) sham-tDCS / 
sertraline-pill (sertraline-only); (3) active-tDCS / placebo-pill (tDCS-only); (4) active-tDCS / 
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sertraline-pill (combined treatment). The trial duration was 6 weeks, encompassing an acute 
treatment phase when ten consecutive daily neuromodulation (tDCS or sham) sessions were 
delivered (from Monday to Friday), followed by two tDCS sessions delivered every other week. 
Sertraline (50mg/day), a selective serotonin reuptake inhibitor (SSRI), treatment duration also 
lasted 6 weeks. Sertraline was chosen because it is an effective antidepressant drug with few 
adverse effects (Cipriani et al., 2009); moreover, previous neurophysiological studies showed that 
tDCS effects are enhanced when combined with the SSRI citalopram (Nitsche et al., 2009). 
 
2.2 Subjects 
 We enrolled subjects with non-psychotic, major depressive disorder in an acute major 
depressive episode. The diagnosis was established by board-certified psychiatrists (ARB and LV) 
using the Portuguese-validated version of the Mini International Neuropsychiatric Interview 
(Amorim, 2000 ). Only participants with at least a moderate depressive episode severity (defined as 
a Hamilton Depression Rating Score, 17-items [HDRS] ≥17) were included. Comorbid anxiety 
disorders were permitted.  
Subjects were excluded if they were not in good physical condition or had any medical 
disorder as determined by physical and neurological examination, review of systems and laboratory 
tests. Other exclusion criteria included pregnancy or breastfeeding, history of substance abuse 
within the past two years, any history of psychotic disorder, bipolar disorder, current suicidal 
ideation, previous non-response to sertraline, or sertraline treatment in the current major depressive 
episode. There were no patients with diabetes melito and anorexia nervosa, conditions associated 
with BDNF changes. 
Subjects who were not drug-naïve in the current depressive episode were gradually tapered 
of any psychotropic medication except for those previously taking a benzodiazepine; in such 
individuals, the dose was tapered to a maximum of 20mg/day of diazepam-equivalents, which 
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remained constant throughout the entire study. Therefore, participants remained free of 
psychotropic medications for at least five half-lives of the medication(s); which corresponded to a 
median washout time period of 18 days ((Brunoni et al., 2011b; Brunoni et al., 2013b) for further 
details).  
In SELECT-TDCS, the primary outcome measure was the score changes of the Portuguese-
validated version of the Montgomery-Åsberg Depression rating scale (MADRS) (Gorenstein et al., 
2000). As a secondary outcome measure, clinical response (≥50% of MADRS improvement from 
baseline to endpoint) was also evaluated.  
 
2.3 Procedures 
 We employed standard, commercial tDCS devices (Chattanooga Ionto™ Dual Channel 
Devices, Chattanooga Group, Hixson, TN 37343 USA). The anode was placed over the left DLPFC 
and the cathode over the right DLPFC (F3 and F4 areas, respectively, according to the 10/20 EEG 
system). The brain areas were localized 5cm laterally and 5cm ventrally from the central of the 
scalp (where the sagittal and coronal planes cross). The bifrontal setup was used in accordance to 
previous studies (Brunoni et al., 2012a; Brunoni et al., 2011a; Dell'Osso et al., 2009; Ferrucci et al., 
2009) as this montage might be advantageous (compared to cathode placement over the right 
supraorbital area) considering the prefrontal activation asymmetry observed in depression, i.e. 
hypoactivity of the left and relative hyperactivity of the right prefrontal cortex (Mayberg et al., 
2000).  
A current density of 0.8A/m2 (2mA/25cm2) for 30 minutes/day was employed. For sham 
condition, we used the method of Gandiga et al. (2006), in which the device is turned on for only a 
brief period of time and then remains turned off for the lasting 29min. This method mimics skin 
side effects (tingling, itching, local discomfort) although the period of active tDCS is too short to 
induce any neuromodulatory effects, which outlast the stimulation (Nitsche and Paulus, 2000).  
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  Blood samples were collected by venipuncture immediately before (2-4 pm) the first and the 
last tDCS session – i.e. at study baseline and endpoint. Within 30 minutes of sample collection, they 
were then spun at 3000 rpm for 15 minutes at 5°C and thereafter plasma aliquots were gently 
collected and stored at -80°C until analysis. Plasma levels of BDNF were measured by enzyme-
linked immunosorbent assay (ELISA) according to the procedures supplied by the manufacturer 
(DuoSet, R&D Systems, Minneapolis, MN, USA). All samples were assayed in duplicate. Lower 
detection limits were 5 pg/mL. Concentrations are expressed as pg/mL. Analyses of blood samples 
were performed blind to group assignment and outcome. 
  
2.4 Statistical analysis 
We used Stata 12 (Statacorp, College Station, TX, USA) for all analyses, with 2-sided 
significance tests at the 5% significance level. For descriptive data, clinical and demographic 
variables were compared across groups using one-way analysis of variance (ANOVA), χ2 tests or 
Fisher’s exact tests, when necessary. Analyses of blood samples were performed blind to group 
assignment.  
 A repeated-measures analysis of variance was performed for the primary outcome. The 
within-subjects factor was time (two levels: first collection and second collection) and the between-
subjects factors were treatment group (four levels: placebo, sertraline-only, tDCS-only and 
combined therapy) and clinical response. We performed different analyses to investigate whether 
BDNF levels would change (1) over time and according to the interactions (2) between time and 
group, (3) between time and clinical response and (4) between time, group and clinical response.  
For the model using all factors (time, group and clinical response), we also performed 
additional analyses to examine whether other characteristics such as sociodemographic 
characteristics (age, gender, obesity – defined as a body mass index ≥30kg/m2, smoking status, 
physical activity - evaluated with the IPAQ questionnaire and further explored in low, moderate and 
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high physical activity for the present analysis); depression characteristics at baseline (melancholic 
depression, atypical depression, severity – with a cut-off point of baseline MADRS≥30, and 
refractoriness – defined as the therapeutic failure to two or more antidepressants in the current 
depressive episode) and benzodiazepine use influenced the outcome. Each variable was explored in 
a separate model.  
 In addition, to further explore whether baseline BDNF levels were predictors of response, 
we used unpaired t-tests to compare responders vs. non-responders. Pearson’s correlations were 
performed to explore the association of changes in BDNF levels with depression scores. 
 
3. Results 
3.1 Overview 
Of the 120 participants enrolled, 103 completed the original study. From the study 
completers, 73 (71%) had their baseline and endpoint BDNF plasma levels analyzed. The remaining 
30 patients were not collected due to patient refusal and technical reasons. Their clinical and 
demographic characteristics did not differ from the completers of the original study and the main 
results from the original study were replicated in this subsample regarding efficacy of clinical 
interventions, that is, all groups presented similar depression scores at baseline, tDCS-only was 
statistically superior to placebo and had similar efficacy as sertraline, and combined treatment was 
superior to all other groups, being also associated with a faster antidepressant response (Brunoni et 
al., 2013b) (Table 1).  
(Table 1)  
3.2 Changes in BDNF plasma levels 
 According to the different models described, we did not find any significant main effects of 
time (F1,153=0.32, p=0.58), and also no interaction effects of time with group (F3,153=0.47, p=0.7), 
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clinical response (F1,153=0.35, p=0.55) and time x group x clinical response (F3,153=0.2, p=0.89). In 
other words, BDNF plasma levels showed no variation over time, regardless of treatment group 
and/or clinical response (Figures 1) (Table 2).  
 (Figure 1) 
(Table 2) 
Finally, when analyzing tDCS and sertraline in the same model as two separate variables 
(i.e., tDCS vs. no-tDCS and sertraline vs. no-sertraline), neither tDCS (40 and 37 patients in the 
active and sham arm, respectively, F1,153=0.33, p=0.58) nor sertraline (39 and 38 participants in the 
real and placebo arm, respectively, F1,153=0.78, p=0.36) changed BDNF plasma levels over time and 
according to clinical improvement.   
 
3.3 Influence of other variables in BDNF plasma levels 
 
 In the model exploring the effects of group and clinical response of BDNF changes over 
time, we also performed several analyses to assess the influence of other variables on outcome 
(only one variable was assessed at a time). We also found no significant effects of gender 
(F1,153<0.01, p=0.95), benzodiazepine use (F1,153=0.01, p=0.91), age (F37,153=0.82, p=0.71), obesity 
(F=0.01, p=0.97), smoking status (F1,153=0.04, p=0.85), physical activity, indexed by the IPAQ 
questionnaire (F2,151=0.41, p=0.63), atypical depression (F1,153=3.21, p=0.07), melancholic 
depression (F1,153=3.22, p=0.07), severe depression at baseline (F1,153=2.59, p=0.11) and 
refractoriness (F1,153=0.67, p=0.77) on the outcome.  
   
3.4 BDNF plasma levels and depression scores 
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There were no significant correlations between MADRS or HDRS scores changes with 
BDNF plasma changes (p=0.55 and 0.56, respectively). Also, no association was significant when 
considering each group separately (ps>0.1). 
 
3.5 BDNF baseline levels as predictors of antidepressant response 
 To assess whether BDNF baseline plasma levels predict depression improvement, we 
performed an analysis of covariance using MADRS depression improvement as dependent variable, 
group as independent variable and BDNF as covariate. No effects for BDNF were found 
(F1,72=0.15, p=0.69), meaning that BDNF levels at baseline were not associated with depression 
improvement. 
 
4. Discussion 
 In this factorial, randomized, placebo-controlled trial we examined BDNF plasma levels in 
73 patients before and after a 6-week treatment course of active/sham tDCS and real/placebo 
sertraline. Our main findings were that, contrary to our initial hypotheses, (1) BDNF plasma levels 
did not significantly increase after tDCS and sertraline interventions, regardless of clinical 
improvement; (2) BDNF baseline levels were not predictors of the antidepressant response and (3) 
an increase in BDNF was not necessary to induce acute antidepressant effects. Only Palm et al. 
(2013) examined BDNF plasma levels after tDCS treatment, finding no increase in BDNF plasma 
levels in 19 participants who received active or sham tDCS. However, in contrast to Palm et al. who 
showed no clinical response after tDCS treatment, tDCS was an effective antidepressant treatment 
in the present study and, in addition, we collected BDNF in subjects who were not taking 
antidepressants at baseline and who were not on concomitant medications (except for 
placebo/sertraline and low-dose benzodiazepines that did not influence the outcome) throughout the 
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trial, factors that may influence BDNF concentrations (Brunoni et al., 2008). In addition, Palm et al. 
attributed their negative results partly to the fact that their sample was mainly composed of patients 
with treatment-resistant depression. However, in our analysis only 40% of the sample was 
refractory, and this variable also did not affect the outcome. Finally, Palm et al. discussed that the 
timeframe between BDNF collections was possibly too short (2 weeks, before the crossover phase) 
to show a BDNF increase, however, we found similar results with a longer timeframe of 6 weeks. 
Therefore, we confirm and expand the results of Palm et al. that BDNF levels do not change after 
tDCS treatment by examining a large sample with different clinical characteristics and in a different 
study design. 
As no other tDCS study evaluated BDNF levels besides Palm et al. and ours, it is important 
to evaluate BDNF blood changes in the context of other somatic therapies. Regarding rTMS, 
Zanardini et al. (2006) observed enhanced BDNF levels after treatment in 16 patients, whereas 
Lang et al. (2006) (n=14) and Gedge et al. (2012) (n=18) showed no changes after rTMS. Finally, 
Yukimasa (2006) observed that BDNF levels increased in rTMS responders (n=9), but not in rTMS 
non-responders (n=16). For ECT, Bocchio-Chiavetto et al. (2006), in 16 treatment-resistant 
depressed patients and, later on, Marano et al. (2007) (n=15), Okamoto et al. (2008) (n=18), 
Piccinni et al. (2009) (n=18) and Haghighi et al. (2013) (n=20) showed an enhancement of BDNF 
levels; whereas Gedge et al. (2012) (n=11) and Fernandes et al. (2009) (n=15) did not show 
enhancement of BDNF levels after ECT. Therefore, most rTMS and ECT studies showed mixed or 
negative findings regarding BDNF increase after treatment. Nonetheless, these studies were 
methodologically limited as most did not employ a sham-controlled design and enrolled patients 
with concomitant antidepressant treatments. In spite of the methodological limitations of previous 
reports, our results are mostly in line with previous findings. It should be noted that our study 
enrolled a large (n=73) sample size to assess BDNF changes after a non-invasive brain stimulation 
intervention, and was the first using an active control (sertraline) and a placebo control. This 
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particular design corroborates our findings, as it allowed us to look at the stability of measures over 
time, ruling out natural fluctuation in the course of illness. 
 Interestingly, BDNF levels did also not increase after sertraline treatment, apparently in 
contrast with meta-analyses showing that BDNF levels increase after diverse pharmacological 
interventions (Brunoni et al., 2008; Molendijk et al., 2013; Sen et al., 2008). One possible reason is 
the low sertraline dose in the present study. However, despite using 50 mg/day of sertraline, 
patients on sertraline (vs. placebo) showed clinical improvement and this was without correlative 
changes in BDNF plasma levels, supporting that changes in BDNF levels are not necessary to acute 
changes in depressive symptoms. In addition, the combined (tDCS/sertraline) group showed greater 
antidepressant effects, although BDNF levels did not change in this group as well. In this context, 
the recent meta-analysis of Molendijk et al. (2013) highlighted evidence for a publication bias in the 
BDNF literature, i.e., studies that showed no BDNF increase after antidepressant treatment might 
not have been published. Another critical point is whether BDNF blood levels does reflect BDNF 
expression in the brain or is rather influenced by peripheral sources such as platelets (Karege et al., 
2002). Although technically challenging, assessment of BDNF levels in the cerebrospinal fluid 
could be an alternative to assess directly the effects of antidepressant therapies on BDNF expression 
in the CNS.  
 One important implication of our results is that we showed that an increase in BDNF was 
not necessary to induce an antidepressant response regardless of the type of the intervention, as in 
all groups clinical response was not associated with BDNF increasing. In this context, BDNF 
baseline levels were not predictors of antidepressant response either, as observed in some 
pharmacological studies (Kurita et al., 2012; Tadic et al., 2011; Wolkowitz et al., 2011) but not in 
all (Umene-Nakano et al., 2010). Nonetheless, although BDNF meta-analyses supported the notion 
that depression improvement is associated with BDNF increasing, virtually all BDNF trials were 
not controlled; therefore it was not possible to disentangle antidepressant treatment effects from 
time effects and also from drug effects in platelets that store BDNF in the blood. Particularly for 
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tDCS, our results are in line with our previous finding that the BDNF Val66Met polymorphism has 
no major impact on tDCS antidepressant response (Brunoni et al., 2013a). In fact, the role of this 
polymorphism on antidepressant drug response is also unclear (Domschke et al., 2010). 
 The main limitation of our study is that, although we enrolled a relatively large sample size 
considering non-invasive brain stimulation trials, the study might have still been underpowered for 
detecting a subtle impact of treatment on BDNF changes; although we controlled for biases 
associated with lower BDNF increase, notably the enrollment of an antidepressant-free sample. 
Therefore, considering the paucity of studies assessing BNDF changes in depressed patients after 
tDCS, further tDCS trials with large sample sizes might be necessary to better define the role of 
BDNF in tDCS antidepressant response. 
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Table 1. Clinical and demographic characteristics of the sample of the present study at baseline. 
 
 
Placebo Sertraline-
only 
tDCS-
only 
Combined 
treatment p Total 
Total 
from the 
original 
study 
p  
 
Clinical characteristics 
Sample size 19 18 15 21 0.79 73 120 -- 
Age, years (SD) 50 (12) 41 (1) 41 (12) 41 (13) 0.1 41 (12) 42 (12) 0.58 
Women, n (%) 12 (63) 11 (61) 10 (66) 18 (85) 0.3 51 (70) 82 (68) 0.77 
Using 
benzodiazepines 
(%) 
2 (10) 2 (11) 1 (7) 5 (23) 0.53 10 (14) 23 (20) 0.3 
BMI, kg/m2 
(SD) 26 (6) 25 (3) 25 (6) 27 (5) 0.54 26 (5) 26 (5) 0.92 
Depression characteristics at baseline, n (%) or mean (SD) 
Refractory 
depression 7 (37) 9 (50) 6 (40) 7 (33) 0.75 29 (40) 50 (42) 0.78 
Severe 
depression 12 (63) 11 (61) 11 (73) 12 (57) 0.8 46 (63) 70 (58) 0.49 
MADRS 31.5 (6) 31 (7) 32 (6) 31 (6) 0.92 31 (6) 31 (6) 0.5 
HDRS17 22 (4) 22 (4) 22(4) 22 (4) 0.99 22(4) 22(4) 0.75 
Depression endpoint scores, mean(SD) and response, n(%) 
MADRS 24 (9) 19 (13) 19 (12) 10 (6) <0.01 18 (11) 19 (11) 0.38 
HDRS17 17 (7) 14 (8) 13 (7) 9 (5) 0.01 14 (8) 15 (7) 0.34 
Response 4 (21) 7 (39) 7 (46) 16 (76) <0.01 34 (46) 47 (39) 0.52 
 
tDCS, transcranial direct current stimulation; MADRS, Montgomery-Asberg depression rating scale; HDRS17, 
Hamilton Depression Rating Scale, 17-items; BMI, body mass index; SD, standard deviation. Refractory depression: 
patients who had failed to respond to  two or more antidepressants in the current major depressive episode.  Severe 
Depression: MADRS ≥ 30. Significant p values (<0.05) are highlighted in bold.  
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Table 2. BDNF plasma levels at baseline and endpoint according to the treatment group and 
clinical response. 
 
BDNF Placebo Sertraline-only tDCS-only Combined treatment 
Baseline 1565 (597) 1331 (786) 1577 (529) 1468 (501) 
Endpoint 1502 (653) 1620 (672) 1588 (297) 1470 (647) 
Responders         
Baseline 1447 (553) 1287 (743) 1709 (393) 1484 (552) 
Endpoint 1421 (357) 1518 (687) 1570 (314) 1446 (726) 
Non-Responders         
Baseline 1603 (623) 1356 (841) 1459 (626) 1420 (349) 
Endpoint 1527 (729) 1695 (685) 1608 (299) 1546 (329) 
BDNF, brain-derived neurotrophic factor; tDCS, transcranial direct current stimulation. Values 
represent mean (standard deviation) of BDNF plasma levels (pg/mL). 
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Figure 1. BDNF plasma levels before and after treatment.  
 
 
Fig1A represents the total sample (n=73), Fig1B displays the results for patients presenting clinical 
response to treatment (n=34) and Fig 1C for treatment non-responders (n=39). BDNF, brain-derived 
neurotrophic factor. Bars represent 1 standard deviation.  
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Figure 1. 
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